论文部分内容阅读
AIM:To investigate the responses of TT virus (TTV) andhepatitis B virus (HBV) to a long-term lamivudine therapy.METHODS:Sixteen patients infected with both TTV andHBV were treated with lamivudine 100 mg daily for 30months.Blood samples were drawn at the beginning of thetherapy and subsequently at month 3,6,9,12 and 30.Serum TTV was quantified by real time PCR and serum HBVwas detected by hybridization assay and nested polymerasechain reaction.RESULTS:TTV infection was detected in 100 % of HBV-infected patients.Loss of serum TTV DNA after one year oftreatment occurred in 1/16 (6 %) patients.At the end oftherapy,TTV DNA was positive in 94 % of them.The declineof HBV viremia was evident at 3 months after therapy andthe response rate was 31%,44 %,63 %,50 % and 50 %at month 3,6,9,12 and 30,respectively.CONCLUSION:TTV replication is not sensitive to lamivudineand is highly prevalent in HBV-infected patients.
AIM: To investigate the responses of TT virus (TTV) and hepatitis B virus (HBV) to a long-term lamivudine therapy. METHODS: Sixteen patients infected with both TTV and HBV were treated with lamivudine 100 mg daily for 30 months. Blood samples were drawn at the beginning of the treatment and subsequent at month 3, 6, 9, 12 and 30. Serum TTV was quantified by real time PCR and serum HBV was detected by hybridization assay and nested polymerase chain reaction .RESULTS: TTV infection was detected in 100% of HBV- infected patients. Loss of serum TTV DNA after one year of treatment occurred in 1/16 (6%) patients. At the end of therapy, TTV DNA was positive in 94% of them. decline of HBV viremia was evident at 3 months after therapy andthe response rates were 31%, 44%, 63%, 50% and 50% at month 3, 6, 9, 12 and 30, respectively.CONCLUSION: TTV replication is not sensitive to lamivudine and is highly prevalent in HBV-infected patients.